MSN Laboratories

About MSN Laboratories

MSN Laboratories was founded in 2003 and is one of the fastest growing pharmaceutical manufacturers of APIs and finished dosages in India. We have Nine API and Five Finished dosage facilities & an integrated R&D Center located in Hyderabad.

Our state-of-the-art facilities are accredited by  USFDA, EU:GMP, WHO:Geneva, PIC/S, ANVISA, Invima and many other global approvals. With a product portfolio covering 35 major therapies including Oncology, MSN reaches out to millions of people in 65 countries across North America, Europe, Latin America, CIS, Middle East, Africa & Asia.  

Our strengths are our world-class facilities, innovation driven R&D, strong IPM, commitment to quality, efficient supply chain and a team with proven track record.

MSN is proud to launch 1st-in-the-World Generics for 16 state-of-the-art-medicines at affordable prices; file 300 patents, 500 DMFs/CEPs , 2000 Formulation Dossiers & more than 40 ANDAs.  With annual capacities over 4 Billion units for the Oral Solids, Injectibles and Oncologics, we support 300 partners across 65 countries in the API and Formulations business.
Integrity, Imagination and Innovation are the ingredients of our or...

  • IN
  • 2015
    On CPHI since
Contact info
Meet us at

CPHI & PMEC China 2024

Shanghai New International Expo Center
19 June 2024 - 21 June 2024

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

CPHI & PMEC India 2024

India Expo Centre, Greater Noida, Delhi NCR
26 Nov 2024 - 28 Nov 2024

MSN Laboratories Resources (1)

  • Brochure MSN corporate overview

    MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 24 state-of-the-art manufacturing facilities (16 API and 8 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly.